Related Experiment Video
Updated: Jul 4, 2026

Direct Reprogramming of Mouse Fibroblasts into Melanocytes
Published on: August 27, 2021
Anaphylactic reaction to recombinant insulin-like growth factor-I
Erika Torjusen1, Jose Calderon, Scott A Rivkees
1Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA.
Abstract:
Mecasermin [rDNA] (Increlex; Tercica, Inc.) is recombinant insulin-like growth factor-I (IGF-I) that has been approved to treat growth failure in children with severe primary IGF-I deficiency. Serious allergic reactions related to Increlex therapy have not been reported. We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.
Related Concept Videos
Allergic Reactions: Anaphylaxis
Allergic Reactions
Hypersensitivity Reactions: Immune-Complex Reactions
Allergic Drug Reactions
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug Toxicity: Allergic Reactions
